Hospital-based laboratories and doctors at the battle line of the Covid-19 pandemic might soon add up a new arrow to the testing toolkit quiver, i.e. Artificial Intelligence (AI). An up to date study conducted by researchers from the University of Vermont in the US and Cedars-Sinai expresses the performance of Biocogniv’s new AI-COVID software. The research team found high accuracy & precision in forecasting the probability of Covid-19 infection making use of routine blood tests, which can help hospitals bring down the number of patients referred for inadequate PCR testing.
“Nine months into this pandemic, we now have a better understanding of how to care for patients with Covid-19,” said lead author and University of Vermont Assistant Professor Timothy Plante, M.D., M.H.S., “but there’s still a big obstruction in Covid-19 diagnosis with PCR testing.” PCR testing is the ongoing standard diagnostic for COVID-19, and needs specific sampling, like a nasal or throat swab, and specialized laboratory equipment to run.
Since the complete blood count and complete metabolic panels both are common laboratory tests often ordered by the emergency departments to get an awareness into other systems, the researchers were successful in training their AI model to analyze changes in these routine tests and assign a probability of the patient being Covid-19 negative with high precision.
Biocogniv Chief Operating Officer Tanya Kanigan, Ph.D., says, “According to data from over 100 US hospitals, the national average turnaround time for COVID-19 tests ordered in emergency rooms is above 24 hours, far from the targeted one-hour turnaround.”
“AI-COVID takes seconds to generate its informative result once these blood tests return, which can then be incorporated by the laboratory into its test interpretation,” says Jennifer Joe, M.D., an emergency physician in Boston, Mass. and Biocogniv’s Chief Medical Officer. “In an efficient emergency department that prioritizes these routine blood tests, the door-to-result time could be under an hour.”
Biocogniv CEO Artur Adib, Ph.D., says, “I’m honored to have such an impressive team of medical scientists from the University of Vermont and Cedars-Sinai as collaborators invalidating this timely model. AI has progressed considerably; the time is now to leverage this powerful tool for new healthcare breakthroughs, and we’re glad to direct it to help hospital laboratories and providers combat the current COVID-19 crisis.”